A Cross-Sectional Survey
[Posted 19/Nov/2026]
AUDIENCE: Hospice & Palliative Nursing, Oncology
KEY FINDINGS: Subcutaneous levetiracetam offers a practical alternative when oral administration is not feasible, particularly in end-of-life care. However, clinicians should recognize that reported coadministration does not establish pharmaceutical compatibility or stability. Further laboratory studies are needed, particularly for levetiracetam combined with morphine or hydromorphone, before compatibility can be assumed in clinical practice.
BACKGROUND: Levetiracetam is increasingly administered through continuous subcutaneous infusion (CSCI) to manage seizures in patients receiving palliative care who cannot take oral medication. However, evidence regarding its stability and compatibility when combined with other medications remains limited. This survey examined current clinical practices and identified priorities for future compatibility testing.
DETAILS: Researchers conducted an online survey of 62 palliative care clinicians representing all Australian states and territories. The survey assessed levetiracetam doses, infusion volumes, diluents, administration devices, infusion duration and commonly combined medications. Levetiracetam was predominantly administered as a continuous 24-hour subcutaneous infusion. Reported daily doses ranged from 250 to 4,000 mg, with infusion volumes of 10-120 mL. The only reported diluents were 0.9% sodium chloride and water for injection.
Morphine and hydromorphone were the most frequently coadministered medications and were identified as the highest priorities for future stability and compatibility testing with levetiracetam. The findings demonstrate considerable variation in subcutaneous levetiracetam administration and highlight the need for laboratory evidence to support medication combinations used in palliative care.
Copyright © Skyscape. All rights reserved.
Source: Beschi, F., Gebresillassie, B. M., Schneider, J, et al. Subcutaneous levetiracetam use in adult palliative care in Australia: A cross-sectional survey. Journal of Palliative Medicine. 2026; 2026; 29(11): 1535-1541. Published: November, 2026. DOI: 10.1177/10966218261463858.
KEY FINDINGS: The findings support an association between higher educational attainment and reduced risk of clinically diagnosed AD that persists after accounting for research participation. This suggests that the potential protective effect of education may involve mechanisms beyond differences in study enrollment, including cognitive reserve. The contrasting findings for clinically diagnosed AD and AD/ADRD highlight the importance of outcome definition in genetic epidemiological research. Studies relying partly on family history or proxy diagnoses may be more vulnerable to selection and ascertainment biases than those using confirmed clinical diagnoses.
Clinicians and researchers should interpret epidemiological associations between education and dementia with consideration of potential participation bias and differences in diagnostic ascertainment. Although the study strengthens evidence for an independent relationship between education and clinically diagnosed AD, Mendelian randomization findings do not establish that increasing educational attainment later in life will directly prevent Alzheimer's disease. Further research using more representative populations and stronger multivariable genetic instruments is warranted. An important limitation is that the genetic datasets were restricted to individuals of European ancestry, which may limit generalizability to other populations.
BACKGROUND: Higher educational attainment has consistently been associated with a lower incidence of Alzheimer's disease (AD). However, this relationship may partly reflect selection and participation biases rather than a direct protective effect of education. Individuals with higher educational levels may be more likely to participate in clinical research, while people with cognitive impairment may be less likely to complete assessments or enroll in studies. These differences can distort observed associations between education and AD risk. This study investigated whether the association between educational attainment and AD reflects a genuine causal relationship or is influenced by participation-related biases. Semantic Scholar
DETAILS: Chatterjee and colleagues conducted a two-sample Mendelian randomization (MR) study using genome-wide association study (GWAS) summary statistics to examine the relationships among educational attainment, research participation, and AD. The analysis incorporated genetic data for educational attainment, three measures of research participation, clinically diagnosed AD, and AD and related dementias (AD/ADRD), which included clinical diagnoses and family history information.
The investigators used fixed-effects inverse variance-weighted analysis as the primary MR approach. Additional analyses included MR-Egger regression, weighted median and mode-based estimators, bidirectional MR, and multivariable Mendelian randomization (MVMR). These methods were used to assess potential confounding, genetic pleiotropy, reverse causation, and the independent effects of education and participation. The educational attainment dataset included 3,037,499 participants, while the primary participation measure, based on completion of an optional UK Biobank Mental Health Questionnaire, included 451,036 participants. The clinically diagnosed AD dataset included 94,437 participants, and the AD/ADRD dataset included 788,989 participants. All included GWAS cohorts were of European ancestry. Semantic Scholar
Genetically predicted educational attainment was associated with a reduced risk of clinically diagnosed AD. Each additional year of education was associated with lower odds of AD (OR, 0.70; 95% CI, 0.63–0.79; p = 8e-10). This association remained significant after adjustment for participation in the multivariable MR analysis (OR, 0.76; 95% CI, 0.62–0.92; p = 0.006), suggesting that participation bias alone did not explain the protective association. However, educational attainment was also associated with increased odds of AD/ADRD (OR, 1.09; 95% CI, 1.02–1.15; p = 0.006). This finding was not supported by sensitivity analyses, indicating that the association was not robust.
Participation in the optional Mental Health Questionnaire was associated with reduced odds of clinically diagnosed AD (OR, 0.325; 95% CI, 0.128–0.326; p = 0.01). Genetic liability to AD was also associated with reduced participation in the questionnaire, suggesting that disease-related factors may influence research enrollment and contribute to selection bias. After adjustment for education, there was limited evidence that participation independently influenced AD risk (OR, 0.58; 95% CI, 0.22–1.51; p = 0.27). The authors also identified low conditional instrument strength in the multivariable analysis, which limits the precision of causal interpretation. Semantic Scholar
Copyright © Skyscape. All rights reserved.
Source: Chatterjee, A., Cavaillès, C., Davies, N. M., et al. Disentangling the Causal Effects of Education and Participation Bias on Alzheimer Disease Using Mendelian Randomization. XXXX. 2025; 11(6): e200307. Published: December, 2025. DOI: 10.1212/NXG.0000000000200307.
KEY FINDINGS: An individualized, sequential treatment strategy may provide an effective approach to managing conjunctival melanocytic lesions across different histopathological grades. Topical chemotherapy may be particularly useful in diffuse lesions that cannot be completely removed surgically, while radiotherapy and additional chemotherapy may have a role in localized full-thickness HG-CMIL and invasive disease. Persistent pigmentation following initial treatment and nonbulbar tumor location warrant particular attention because of their association with local recurrence. In invasive conjunctival melanoma, ulceration, nonbulbar involvement, and greater tumor thickness may help identify patients at increased risk of metastatic spread. The findings should be interpreted in the context of the study's retrospective, single-center design, incomplete long-term follow-up in some patients, and limited metastatic events. Further multicenter research is needed to establish the comparative effectiveness of individual treatment modalities.
BACKGROUND: Conjunctival melanocytic lesions range from low-grade conjunctival melanocytic intraepithelial lesions (LG-CMIL) to high-grade lesions (HG-CMIL) and invasive conjunctival melanoma (iCoM). Their management can be challenging because of variations in disease extent, histopathological grade, and risk of local recurrence and metastasis. A sequential treatment strategy combining surgical biopsy, topical chemotherapy, and radiotherapy may help achieve disease control while tailoring treatment to individual lesion characteristics.
DETAILS: This single-center retrospective study, conducted at the Liverpool Ocular Oncology Centre, evaluated patients diagnosed with conjunctival melanocytic lesions between 2015 and 2025. The investigators assessed outcomes following an individualized, stepwise treatment approach based on histopathological findings and the clinical pattern of lesion growth. Treatment included excisional or incisional biopsy, topical chemotherapy, and adjuvant radiotherapy when indicated. The analysis included 165 eyes: 39 with LG-CMIL, 39 with HG-CMIL, and 87 with invasive conjunctival melanoma. Kaplan-Meier analysis and Cox proportional hazards regression were used to evaluate factors associated with local recurrence and metastatic disease. Particular attention was given to residual pigmentation following treatment, tumor location, ulceration, and tumor thickness. HG-CMIL lesions demonstrated the highest local recurrence rate (24.3%) and the shortest median time to recurrence (8.2 months). These lesions were frequently diffuse (71.1%), initially managed with incisional biopsy (59.0%), and associated with persistent residual pigmentation (55.6%). Local recurrence rates were 11.1% for LG-CMIL and 15.0% for invasive conjunctival melanoma. Across all lesion types, nonbulbar involvement (HR 2.76) and residual pigmentation after primary treatment (HR 2.77) were associated with increased local recurrence risk. Metastatic disease occurred exclusively in patients with invasive conjunctival melanoma, affecting 11.4% of this group. Independent risk factors associated with metastasis included ulcerative features (HR 15.08), nonbulbar involvement (HR 7.28), and increased tumor thickness (HR 2.15).
KEY FINDINGS: Avatrombopag significantly improved platelet recovery and reduced the likelihood of recurrent CIT that would interfere with chemotherapy delivery in patients with GI cancers. The oral administration and once-daily dosing may offer a practical approach to managing persistent CIT. However, the trial enrolled only 47 patients and was stopped early for efficacy, which may affect the precision of the estimated treatment benefit. The findings establish efficacy for the study's platelet and chemotherapy-delivery endpoints, but do not demonstrate improved cancer survival or other long-term oncologic outcomes. Larger studies are needed to establish the durability of benefit, broader safety profile, and impact on cancer treatment outcomes. ASCO Publications
BACKGROUND: Chemotherapy-induced thrombocytopenia (CIT) is a clinically important complication of cytotoxic cancer treatment. Persistent thrombocytopenia can lead to repeated chemotherapy delays, dose reductions, and compromised treatment intensity, potentially affecting cancer outcomes. Management remains challenging because widely available approved therapies are limited. Avatrombopag, an oral thrombopoietin receptor agonist, stimulates platelet production and may offer an alternative to injectable therapies for patients with persistent CIT. The ACT-GI trial evaluated its efficacy and safety in patients with gastrointestinal (GI) cancers receiving cytotoxic chemotherapy.
DETAILS: ACT-GI was a multicenter, randomized, double-blind, placebo-controlled, investigator-initiated phase II trial conducted in the United States. Adults with GI cancers and persistent CIT were randomly assigned in a 1:1 ratio to receive avatrombopag or placebo. Persistent CIT was defined as a platelet count of ≤85 x 109/L on the first day of a chemotherapy cycle, despite sufficient time for recovery from the preceding cycle. The primary endpoint was successful platelet recovery to ≥100 x 109/L, completion of the on-study chemotherapy cycle without dose modification or delay due to thrombocytopenia, and prevention of CIT recurrence at the subsequent cycle. Treatment began with avatrombopag 40 mg once daily, with protocol-directed dose adjustments. The trial enrolled 47 patients, including 23 assigned to avatrombopag and 24 to placebo. Enrollment was stopped at a planned interim analysis after prespecified efficacy criteria were met. The primary endpoint was achieved by 16 of 23 patients receiving avatrombopag (70%; 95% CI, 47 to 87) compared with 4 of 24 patients receiving placebo (17%; 95% CI, 5 to 37; Z = 3.67, P .001). Platelet recovery to ≥100 x 109/L during the initial treatment period occurred in 19 of 23 patients (83%) in the avatrombopag group and 11 of 24 patients (46%) in the placebo group. At the end of the chemotherapy treatment period, median platelet counts were 157 (IQR, 136-202) x 109/L with avatrombopag and 72 (IQR, 68-134) x 109/L with placebo. Adverse events occurred in 78% of patients receiving avatrombopag and 46% receiving placebo. Serious adverse events were reported in 17% and 0%, respectively. No serious adverse events were attributed to the study drug, and no treatment-related adverse events resulted in death or discontinuation of study medication.
Copyright © Skyscape. All rights reserved.
Source: Al-Samkari, H., Shatzel, J. J., Panch, S.R., et al. Avatrombopag Versus Placebo for Persistent Chemotherapy-Induced Thrombocytopenia in GI Cancers: The Phase II ACT-GI Trial. Journal of Clinical Oncology. 2026; 44(31): 3006-3014. Published: November 1, 2026. DOI: 10.1200/JCO-26-00568.
KEY FINDINGS: Lean MASLD may carry substantial hepatic and oncological risks despite the absence of obesity. Clinicians should avoid relying on BMI alone when assessing disease severity and should consider liver complications and associated comorbidities in patients with steatotic liver disease across body-weight categories.
The study's retrospective design and reliance on hospitalization data are important limitations. The findings do not establish causality and may not be generalizable to all individuals with MASLD, particularly those managed in outpatient settings. Further research is needed to clarify the mechanisms underlying these associations and determine how risk assessment and management should be tailored to lean patients.
BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is an important cause of chronic liver disease and related complications. Although it is commonly associated with overweight and obesity, the condition also occurs in individuals with a lean body mass index (BMI). The clinical risks in this population remain an important area of investigation, particularly because normal body weight may not reliably indicate the absence of advanced liver disease or metabolic dysfunction.
DETAILS: Researchers conducted a retrospective comparative study using the US National Inpatient Sample (NIS) database from 2016 through 2020. Adult hospitalizations involving MASLD were identified, with exclusions for other specified liver conditions, including viral hepatitis, alcoholic hepatitis, primary biliary cholangitis, hereditary hemochromatosis, autoimmune hepatitis, and Wilson disease. Outcomes were compared between patients classified as lean and those with nonlean BMI. The analysis assessed mortality, hepatic complications, and gastrointestinal malignancies among hospitalized patients with MASLD.
Hospitalized patients with lean MASLD had significantly higher odds of mortality than those with nonlean MASLD (odds ratio, 2.10; P .001). The lean group also had higher odds of cirrhosis, portal hypertension, spontaneous bacterial peritonitis (SBP), and ascites.
In addition, lean MASLD was associated with higher odds of several gastrointestinal malignancies, including esophageal, gastric, pancreatic, and colorectal cancers. These findings suggest that lean body weight should not be interpreted as a reliable indicator of lower clinical risk in patients hospitalized with MASLD.
Copyright © Skyscape. All rights reserved.
Source: Desai, C., Lohani, S., Sharma, A. R., et al. Lean Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comparative Analysis of Hepatic and Oncological Outcomes. Journal of Clinical Gastroenterology. 2026; 60(10): 922-926. Published: November/December 2026. DOI: 10.1097/MCG.0000000000002153.s
KEY FINDINGS: Lecanemab treatment was associated with heterogeneous changes across plasma biomarkers, indicating that amyloid clearance does not produce a uniform response across biological pathways involved in Alzheimer’s disease. Changes in inflammatory and neurodegeneration-related markers may reflect immune responses to amyloid plaques or treatment-related effects on neuronal and synaptic processes.
These findings suggest that different biomarkers could eventually serve distinct clinical purposes, including monitoring treatment response and estimating prognosis. However, the observational design does not establish that individual biomarker changes predict clinical benefit or adverse outcomes. Further validation is needed before these trajectories can guide treatment decisions in routine practice.
BACKGROUND: Lecanemab, an anti-amyloid antibody, can slow cognitive and functional decline in patients with early symptomatic Alzheimer’s disease. However, its effects on circulating biomarkers associated with neurodegeneration, inflammation, and synaptic function remain incompletely characterized. Understanding these changes could help clinicians assess treatment response and identify biomarkers that may eventually inform prognosis.
DETAILS: This longitudinal cohort study, published in The Lancet Neurology, evaluated changes in 130 plasma protein biomarkers among patients receiving lecanemab as part of routine clinical care at the Washington University Memory Diagnostic Center in St Louis, Missouri. The study included 197 patients who had initiated treatment and were followed for up to two years, with clinical assessments and blood collection approximately every six months. Lecanemab was administered intravenously at 10 mg/kg every two weeks. The comparison groups comprised 1,312 participants with cognitive impairment who had not received anti-amyloid antibody treatment and 458 cognitively unimpaired participants without evidence of amyloid-beta positivity. Investigators examined biomarker trajectories and their associations with treatment exposure, amyloid PET status, and cognitive changes.
Of the 130 plasma biomarkers evaluated, 34 demonstrated statistically significant changes during lecanemab treatment after correction for multiple comparisons. The biomarkers followed four distinct patterns.
The first group showed partial normalization, with concentrations moving toward those observed in cognitively unimpaired individuals without amyloid positivity. Examples included phosphorylated tau 217 (p-tau217), microtubule-associated protein tau (MAPT), and glial fibrillary acidic protein (GFAP).
A second group, including amyloid-beta peptides, initially moved toward the reference range but subsequently shifted beyond it, suggesting an overcorrection rather than simple normalization.
A third group showed changes in the opposite direction, moving farther from the concentrations observed in the cognitively unimpaired, amyloid-negative group. These included neuronal pentraxin receptor (NPTXR), neurogranin (NRGN), and triggering receptor expressed on myeloid cells 2 (TREM2).
Other biomarkers, including neurofilament light (NEFL) and apolipoprotein E (APOE), remained comparatively unchanged.
Copyright © Skyscape. All rights reserved.
Source: Mu, R., Hofmann, A., Gong, K., et al. Dynamic changes in plasma biomarkers of Alzheimer's disease in patients treated with lecanemab: a longitudinal cohort study. The Lancet Neurology. 2026; 25(11): 997-1009. Published: November, 2026. DOI: 10.1016/S1474-4422(26)00284-X.
Specialty: